Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice

Huijing Fu, Jingjie Zhang, Jing Pan, Qi Zhang, Yan Lu, Weidong Wen, Ronald A. Lubet, Eva Szabo, Ruth Chen, Yian Wang, Da Ren Chen, Ming You

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Budesonide, a synthetic glucocorticoid used for treating asthma, and pioglitazone, a synthetic peroxisome proliferator-activated receptors γ ligand used for the treatment of diabetes, were evaluated for their combinational chemopreventive efficacy on mouse lung cancer using female A/J mice with benzo(a)pyrene used as the carcinogen. All chemopreventive treatments began 2-wk post-carcinogen treatment and continued daily for 20wk. Budesonide was administered by the aerosol route using an improved aerosol delivery system. Pioglitazone was introduced by oral gavage. The characterization of drug distribution showed that budesonide introduced by aerosol delivery accumulated only in the lung. Budesonide alone reduced tumor load by 78% and pioglitazone alone reduced tumor load by 63%. By combining aerosolized budesonide with pioglitazone, the inhibition on tumor load was 90%. In vitro experiments using human cancer cells showed that budesonide and pioglitazone exhibited independent, additive inhibitory effects on cell growth. Our results provide evidence that aerosolized budesonide and oral pioglitazone could be a promising drug combination for lung cancer chemoprevention.

Original languageEnglish (US)
Pages (from-to)913-921
Number of pages9
JournalMolecular Carcinogenesis
Volume50
Issue number12
DOIs
StatePublished - Dec 2011
Externally publishedYes

Fingerprint

pioglitazone
Budesonide
Chemoprevention
Carcinogenesis
Lung
Tumor Burden
Aerosols
Carcinogens
Lung Neoplasms
Peroxisome Proliferator-Activated Receptors
Benzo(a)pyrene
Drug Combinations
Glucocorticoids

Keywords

  • Budesonide
  • Chemoprevention
  • Lung tumorigenesis
  • Mouse
  • Pioglitazone

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology

Cite this

Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice. / Fu, Huijing; Zhang, Jingjie; Pan, Jing; Zhang, Qi; Lu, Yan; Wen, Weidong; Lubet, Ronald A.; Szabo, Eva; Chen, Ruth; Wang, Yian; Chen, Da Ren; You, Ming.

In: Molecular Carcinogenesis, Vol. 50, No. 12, 12.2011, p. 913-921.

Research output: Contribution to journalArticle

Fu, H, Zhang, J, Pan, J, Zhang, Q, Lu, Y, Wen, W, Lubet, RA, Szabo, E, Chen, R, Wang, Y, Chen, DR & You, M 2011, 'Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice', Molecular Carcinogenesis, vol. 50, no. 12, pp. 913-921. https://doi.org/10.1002/mc.20751
Fu, Huijing ; Zhang, Jingjie ; Pan, Jing ; Zhang, Qi ; Lu, Yan ; Wen, Weidong ; Lubet, Ronald A. ; Szabo, Eva ; Chen, Ruth ; Wang, Yian ; Chen, Da Ren ; You, Ming. / Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice. In: Molecular Carcinogenesis. 2011 ; Vol. 50, No. 12. pp. 913-921.
@article{931795167a0940b0983134098da21455,
title = "Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice",
abstract = "Budesonide, a synthetic glucocorticoid used for treating asthma, and pioglitazone, a synthetic peroxisome proliferator-activated receptors γ ligand used for the treatment of diabetes, were evaluated for their combinational chemopreventive efficacy on mouse lung cancer using female A/J mice with benzo(a)pyrene used as the carcinogen. All chemopreventive treatments began 2-wk post-carcinogen treatment and continued daily for 20wk. Budesonide was administered by the aerosol route using an improved aerosol delivery system. Pioglitazone was introduced by oral gavage. The characterization of drug distribution showed that budesonide introduced by aerosol delivery accumulated only in the lung. Budesonide alone reduced tumor load by 78{\%} and pioglitazone alone reduced tumor load by 63{\%}. By combining aerosolized budesonide with pioglitazone, the inhibition on tumor load was 90{\%}. In vitro experiments using human cancer cells showed that budesonide and pioglitazone exhibited independent, additive inhibitory effects on cell growth. Our results provide evidence that aerosolized budesonide and oral pioglitazone could be a promising drug combination for lung cancer chemoprevention.",
keywords = "Budesonide, Chemoprevention, Lung tumorigenesis, Mouse, Pioglitazone",
author = "Huijing Fu and Jingjie Zhang and Jing Pan and Qi Zhang and Yan Lu and Weidong Wen and Lubet, {Ronald A.} and Eva Szabo and Ruth Chen and Yian Wang and Chen, {Da Ren} and Ming You",
year = "2011",
month = "12",
doi = "10.1002/mc.20751",
language = "English (US)",
volume = "50",
pages = "913--921",
journal = "Molecular Carcinogenesis",
issn = "0899-1987",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice

AU - Fu, Huijing

AU - Zhang, Jingjie

AU - Pan, Jing

AU - Zhang, Qi

AU - Lu, Yan

AU - Wen, Weidong

AU - Lubet, Ronald A.

AU - Szabo, Eva

AU - Chen, Ruth

AU - Wang, Yian

AU - Chen, Da Ren

AU - You, Ming

PY - 2011/12

Y1 - 2011/12

N2 - Budesonide, a synthetic glucocorticoid used for treating asthma, and pioglitazone, a synthetic peroxisome proliferator-activated receptors γ ligand used for the treatment of diabetes, were evaluated for their combinational chemopreventive efficacy on mouse lung cancer using female A/J mice with benzo(a)pyrene used as the carcinogen. All chemopreventive treatments began 2-wk post-carcinogen treatment and continued daily for 20wk. Budesonide was administered by the aerosol route using an improved aerosol delivery system. Pioglitazone was introduced by oral gavage. The characterization of drug distribution showed that budesonide introduced by aerosol delivery accumulated only in the lung. Budesonide alone reduced tumor load by 78% and pioglitazone alone reduced tumor load by 63%. By combining aerosolized budesonide with pioglitazone, the inhibition on tumor load was 90%. In vitro experiments using human cancer cells showed that budesonide and pioglitazone exhibited independent, additive inhibitory effects on cell growth. Our results provide evidence that aerosolized budesonide and oral pioglitazone could be a promising drug combination for lung cancer chemoprevention.

AB - Budesonide, a synthetic glucocorticoid used for treating asthma, and pioglitazone, a synthetic peroxisome proliferator-activated receptors γ ligand used for the treatment of diabetes, were evaluated for their combinational chemopreventive efficacy on mouse lung cancer using female A/J mice with benzo(a)pyrene used as the carcinogen. All chemopreventive treatments began 2-wk post-carcinogen treatment and continued daily for 20wk. Budesonide was administered by the aerosol route using an improved aerosol delivery system. Pioglitazone was introduced by oral gavage. The characterization of drug distribution showed that budesonide introduced by aerosol delivery accumulated only in the lung. Budesonide alone reduced tumor load by 78% and pioglitazone alone reduced tumor load by 63%. By combining aerosolized budesonide with pioglitazone, the inhibition on tumor load was 90%. In vitro experiments using human cancer cells showed that budesonide and pioglitazone exhibited independent, additive inhibitory effects on cell growth. Our results provide evidence that aerosolized budesonide and oral pioglitazone could be a promising drug combination for lung cancer chemoprevention.

KW - Budesonide

KW - Chemoprevention

KW - Lung tumorigenesis

KW - Mouse

KW - Pioglitazone

UR - http://www.scopus.com/inward/record.url?scp=80155129711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80155129711&partnerID=8YFLogxK

U2 - 10.1002/mc.20751

DO - 10.1002/mc.20751

M3 - Article

VL - 50

SP - 913

EP - 921

JO - Molecular Carcinogenesis

JF - Molecular Carcinogenesis

SN - 0899-1987

IS - 12

ER -